We are live on ! Find out more
HAE icon

Haemonetics

296 hedge funds and large institutions have $5.49B invested in Haemonetics in 2021 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 101 increasing their positions, 105 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 40

3% more funds holding

Funds holding: 286296 (+10)

10% more call options, than puts

Call options by funds: $11M | Put options by funds: $10M

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

0.29% less ownership

Funds ownership: 97.89%97.6% (-0.29%)

4% less repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 105

7% less capital invested

Capital invested by funds: $5.89B → $5.49B (-$398M)

Holders
296
Holders Change
+10
Holders Change %
+3.5%
% of All Funds
5.2%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
52
Increased
101
Reduced
105
Closed
40
Calls
$11M
Puts
$10M
Net Calls
+$977K
Net Calls Change
+$3.92M

HAE Hedge Fund Activity: Q1 2021 in Review

296 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2021, worth a combined $5.49B — down 6.8% from $5.89B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new HAE positions and 40 closed out — a net gain of 12 holders — while 101 added to existing stakes and 105 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $105M. The largest seller was Wells Fargo, cutting an estimated $82.3M.

  • 296 institutional investors held Haemonetics (HAE) as of Q1 2021, up from 286 in Q4 2020.
  • Funds reported $5.49B of Haemonetics stock for Q1 2021, down 6.8% quarter-over-quarter.
  • 52 funds opened new Haemonetics positions in Q1 2021 and 40 closed out, a net change of +12 holders.
  • The largest Haemonetics buyer in Q1 2021 was OrbiMed, an estimated $105M added.
  • The largest Haemonetics seller in Q1 2021 was Wells Fargo, an estimated $82.3M sold.

Based on aggregated 13F filings for Q1 2021.